Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stock Scan October: Generics Pull Pharma Down

Executive Summary

Pharma stocks suffered in October, particularly in North America. Across the globe, stock prices among the biggest pharmaceutical companies were down an average of 2% on the month, despite general market revivals in Asia. The generics sector was particularly badly hit but there were several major setbacks for branded pharma companies, too.

You may also be interested in...



Stock Scan Q4 2017 – Q3 Reporting Chops $70bn From Pharma

Big pharma stocks lost value overall in the fourth quarter of 2017 despite good performances from Asian companies and Kåre Schultz taking over at Teva.

Stock Scan November 2017: Generics get volatile

Generic drug producers endured very mixed fortunes on the world's stock markets, with firms ending November at opposite ends of Scrip's Stock Scan monthly league table.

Quarterly Reporting: Investor Reality Check Or Pharma Communication Gap?

Multi-billion dollar gaps exist between what investors think a company is worth one day and what they think the next. A Scrip analysis shows that these information gaps between big pharma and their shareholders are very common and are often bridged only by the mandatory quarterly reporting from companies. While unbalanced optimism or pessimism from investors might account for some of the chasm in understanding, an absence of interim guidance from companies is also a factor.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel